🎯 Today's Earnings Calls Pulse

Boston Scientific faces a reset as shares tumble 53% after FY26 outlook cut
Boston Scientific’s stock has fallen about 53% over the past year after the company slashed its FY26 outlook, citing slower growth for its WATCHMAN atrial‑appendage closure device and mixed results from the CHAMPION‑AF trial. Management now projects organic revenue growth of 6.5‑8% and earnings of $3.34‑$3.41 per share, down from prior guidance.